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stringent regulations to protect experimental research data from third-party access.
(Recommendation 1.)
Unlike clinically validated medical information obtained for patient care, experimental research data often lack analytical
and clinical validity. This means that research data may be clinicaily meaningless
or misleading. Research studies to identify
the genetic basis of a specific disease may
generate very preliminary, inconclusive, or
invalid experimental information linking a
genetic alteration with risk of developing
the disease. Unless a research protocol includes the clinical care of the research participant, experimental research data should
be kept in the researcher's scientific files
and not placed in the participant's medical
record (11). (Recommendation 2.)
Individuals who participate in research
are protected by the Common Rule (12),
which requires that all research with human subjects that is supported, conducted,
or regulated by federal agencies must be
reviewed by an institutional review board
(IRB). IRBs are responsible for ensuring
that the participants' consent is informed
and voluntary, that risks to the participants
are minimized, and that the participants'
rights and welfare are protected. IRBs also
consider whether the proposed informed
consent document includes "a statement
describing the extent, if any, to which confidentiality of records identifying the subject will be maintained" (13). The IRB
guidebook recommends that data should
not be released except as authorized by the
research subject and that subsequent re-
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apid progress in the Human Genome
Project has heightened public awareness of the positive impact of genetics research on human health. Along with
these positive effects have come concerns
about who will have access to personal genetic information and how it will be used.
Here, we present policy recommendations
(see the table) for protecting the privacy of
genetic information in research (1).
A particular person's genetic information may be of interest to a wide variety of
individuals and organizations. Insurers
and employers may
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Family members,
educational institutions, or the courts (in
cases where custody is being challenged,
for example) may also want access to genetic information. Indeed, genetic information has already been used to deny
medical benefits to retirees with illnesses
with a known genetic basis (2). Cases of
insurance and employment discrimination
based on genetic information have also
been reported (3).
Recommendations to restrict use of genetic information in health insurance and in
the workplace have been developed by the
National Action Plan on Breast Cancer
(NAPBC) and the National Human Genome
Research Institute (NHGRI) (4). State and
federal laws restrict some uses of genetic information in health insurance and the workplace (5. 6). Nevertheless, comprehensive
federal protections are not in place (7).
The privacy of medical information is
protected principally by state law, although
the level of protection varies widely from
state to state. These laws· generally restrict
access to health-care records to those with
signed authorizations or a court order, or
in other limited circumstances.
The Federal Privacy Act of 1974 safeguards health, research, and other records
held by federal agencies. Nevertheless,

R

there are many instances in which disclosures without the consent of the individual
are allowable. Other than federal statutes to
protect research specific to crimes, healthcare outcomes, or medical liability, there
are no comprehensive federal laws to protect the privacy of research information (8).
Currently, the U.S. Congress is considering measures to protect the privacy and
confidentiality of individually identifiable
health information (9). Pending legislation
addresses the responsibilities of individuals and organizations who maintain health
information, describes who can have access to individual medical records, and
outlines the process for obtaining access.
Of concern to the scientific community
is the danger that experimental research
records might be included inappropriately
in the broad definitions of individually
identifiable health information (1 0). Although it may seem paradoxical, inclusion
of these records could allow unnecessary
and inappropriate third-party access to this
information (such as by law enforcement
officials or courts). The social value of research, the altruistic nature of research
participation, and the reliance of the research enterprise on volunteers necessitate
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quests for information should be subject to
ically meaningless or misleading, thus
the agreements in the informed consent
lacking the clinical and analytical validity
of medical records (21).
(14). However, current practices are diIn a specific case, 5209 people were reverse, and there are no specific mandates
cruited to participate in a longitudinal study
or requirements for even the most basic
of factors that contribute to cardiovascular
levels of privacy and confidentiality prodisease (22). Subsequently, the study entections. (Recommendation 3.)
The public focus has been on privacy of rolled another 5124 adult children and
spouses of the original group. The subjects
information acquired in the clinical setting
gave permission for genetic studies, the col(15); privacy of experimental research data
lection of medical histories, and physical
has received comparably little attention.
There has been no systematic analysis of examinations. Tests were performed in a remethodologies used to protect privacy of search laboratory that can tolerate a l to 2%
error rate that would not be tolerated in a
research records or of breaches of conficlinical laboratory because the study was
dentiality. An assessment of current pracevaluating the significance of genetic varitices and development of best practices to
ants among thousands of persons, not the
protect research data from third-party acrelevance to one individual.
cess is needed. (Recommendation 4.)
Concern about sample
As early as 1977, the Federal Privacy
integrity as well as anaProtection Study Comlytical and clinical validimission strongly favored
ty of medical tests pro"statutory immunity which
vides the basis for a fedprotects the rights and ineral law (CLIA) that reterests of the individual"
research data
quires laboratories proresearch participant (16).
viding data back to paThe Public Health Service
should be kept
tients to meet a number
Act provides for Certifiof quality standards (23).
cates of Confidentiality
in the
Many research laborato(17) that protect personalries are not CLIA aply identifiable research inresearcher's
proved. Consequently,
formation. These certifithere is concern that
cates can be obtained by
scientific files
transmitting the outcome
privately funded as well
of these studies to the reas federally funded reand not placed
search participants would
search projects of a sensiresult
in the transmission
tive nature, including proin the
of false-positive or falsejects involving informanegative results.
tion that "could reasonparticipant's
Providing such data to
ably lead to social stigmasubjects may entail sigtization or discrimination"
medical record."
nificant risks and cause
(18). They provide a legal
erroneous conclusions to
defense for researchers
be made that could result
against compelled discloin physical, psychosocial, or economic
sure of identifiable research information as
harms. If genetic research results are to be
a result of a subpoena or court order (19)
given to the subjects, the protocol must
and can be a critical device for the protecprovide for counseling before and after the
tion of genetic research data (20). Howevtest (24). For a study with about l 0,000
er, they do not provide legal protection for
participants, the cost of counseling is estiresearch participants from compelled dismated to be more than $500,000 per year.
closure. (Recommendation 5.)
Although this cost is warranted in studies
It is universally accepted that individuthat generate data useful to individual parals should have access to their own mediticipants, in the case described above the
cal information. At first examination, it
expenditure may be unwarranted. If a poliseems straightforward to conclude that this
cy mandating return of clinically meaningshould apply to experimental research daless data were implemented, associated
ta. There are several key characteristics,
costs and personnel might provide an obhowever, that differentiate medical inforstacle to doing the study. Thus, in the abmation from experimental research data.
sence of clinical validity there should not
Unlike medical records, research records
be an absolute requirement for data to be
contain experimental data and analyses
returned to subjects. For research in which
necessary to test hypotheses. The clinical
data are not provided to subjects, the resignificance of the results of a particular
experiment may only be established after searcher should demonstrate absence of
clinical validity, an IRB should be required
many years of additional research, if ever.
to review and approve the exception, and
This means that research data may be clin-
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the informed consent document should
state explicitly that the data will not be returned to the research subject. (Recommendation 6.)
Implementation of our recommendations is imperative to maintain the trust
placed in the research process and to realize the potential of genetics research to
benefit human health.
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